Jiang Y
Cancer Institute of China Medical University, Shenyang.
Zhonghua Zhong Liu Za Zhi. 1993 May;15(3):198-201.
A monoclonal antibody against human pancreatic carcinoma APCA-1, was developed. By immunohistochemical staining, it had pretty good reactivity to carcinoma of the pancreas, bile duct and gall bladder. Their positive rates were 94.1%, 80% and 75%, respectively. It cross reacted weakly with normal epithelial cells of the pancreas, gall bladder and bile duct in relatively low frequency. Immunoscintigraphy was performed in nude mice with xenograft of human pancreatic cancer using 131I-labeled APCA. Good radio-imaging of the tumor xenograft was achieved. The ratio of radioactivity of each gram of tumor tissue to total radioactivity reached 5.1%, 6.9% and 6.2% at 72,120 and 168 hr respectively.
一种抗人胰腺癌的单克隆抗体APCA-1被研制出来。通过免疫组织化学染色，它对胰腺癌、胆管癌和胆囊癌具有相当好的反应性。它们的阳性率分别为94.1%、80%和75%。它与胰腺、胆囊和胆管的正常上皮细胞有较弱的交叉反应，频率相对较低。用131I标记的APCA对人胰腺癌异种移植裸鼠进行免疫闪烁显像。肿瘤异种移植获得了良好的放射性显像。每克肿瘤组织的放射性与总放射性之比在72、120和168小时分别达到5.1%、6.9%和6.2%。
